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Abstract
Introduction Glycolysis is increased in breast adenocarcinoma
cells relative to adjacent normal cells in order to produce the
ATP and anabolic precursors required for survival, growth and
invasion. Glycolysis also serves as a key source of the reduced
form of cytoplasmic nicotinamide adenine dinucleotide (NADH)
necessary for the shuttling of electrons into mitochondria for
electron transport. Lactate dehydrogenase (LDH) regulates
glycolytic flux by converting pyruvate to lactate and has been
found to be highly expressed in breast tumours. Aspartate
aminotransferase (AAT) functions in tandem with malate
dehydrogenase to transfer electrons from NADH across the
inner mitochondrial membrane. Oxamate is an inhibitor of both
LDH and AAT, and we hypothesised that oxamate may disrupt
the metabolism and growth of breast adenocarcinoma cells.
Methods We examined the effects of oxamate and the AAT
inhibitor amino oxyacetate (AOA) on 13C-glucose utilisation,
oxygen consumption, NADH and ATP in MDA-MB-231 cells.
We then determined the effects of oxamate and AOA on normal
human mammary epithelial cells and MDA-MB-231 breast
adenocarcinoma cell proliferation, and on the growth of MDA-
MB-231 cells as tumours in athymic BALB/c female mice. We
ectopically expressed AAT in MDA-MB-231 cells and examined
the consequences on the cytostatic effects of oxamate. Finally,
we examined the effect of AAT-specific siRNA transfection on
MDA-MB-231 cell proliferation.
Results We found that oxamate did not attenuate cellular
lactate production as predicted by its LDH inhibitory activity, but
did have an anti-metabolic effect that was similar to AAT
inhibition with AOA. Specifically, we found that oxamate and
AOA decreased the flux of 13C-glucose-derived carbons into
glutamate and uridine, both products of the mitochondrial
tricarboxylic acid cycle, as well as oxygen consumption, a
measure of electron transport chain activity. Oxamate and AOA
also selectively suppressed the proliferation of MDA-MB-231
cells relative to normal human mammary epithelial cells and
decreased the growth of MDA-MB-231 breast tumours in
athymic mice. Importantly, we found that ectopic expression of
AAT in MDA-MB-231 cells conferred resistance to the anti-
proliferative effects of oxamate and that siRNA silencing of AAT
decreased MDA-MB-231 cell proliferation.
Conclusions We conclude that AAT may be a valid molecular
target for the development of anti-neoplastic agents.
Introduction
Increased uptake of glucose as an anaerobic source of energy
and biosynthetic precursor is a common feature of primary and
metastatic breast adenocarcinomas. Positron-emission tomo-
graphic (PET) studies with 2-[18F]fluoro-2-deoxy-glucose have
consistently demonstrated that human breast tumours trans-
port increased glucose relative to adjacent normal breast tis-
sues  in vivo [1]. Understanding the regulation of glucose
uptake and metabolism in breast cancer may therefore provide
new metabolic targets for the development of anti-breast can-
cer agents.
The proto-oncogene c-myc is amplified in breast tumours and
is associated with an increased risk of relapse and death [2].
AAT: aspartate aminotransferase; AOA: amino oxyacetate; BSA: bovine serum albumin; EDTA: ethylenediaminetetraacetic acid; FCS: fetal calf serum; 
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C-myc induces increased glycolytic flux in cancer cells partly
through transcriptional promotion of lactate dehydrogenase
(LDH) A, a glycolytic enzyme required for c-myc-driven growth
[3]. LDH-A is a reversible enzyme that converts pyruvate to lac-
tate and oxidises the reduced form of nicotinamide adenine
dinucleotide (NADH) to NAD+ [4,5]. LDH-A expression and
activity is increased in malignant relative to normal breast tis-
sues [6,7]. LDH-A is also upregulated by the transcription fac-
tor, hypoxia inducible factor 1α (HIF-1), which is a central
regulator of the metabolic response to hypoxia. HIF-1α is over-
expressed in breast tumours and is positively associated with
proliferation and therefore poor outcome in breast cancer
[8,9]. Finally, LDH activity is increased by oestrogen and oes-
trogen receptor-positive breast tumours express increased
LDH-A levels relative to adjacent normal tissues [10,11].
Taken together, these data suggest that LDH may be a rational
target for the development of agents that disrupt the glycolytic
metabolism of breast cancer cells.
LDH is composed of two separately encoded subunits, A and
B, that combine to form binomial distributions of the five
expected LDH tetramers: LDH1-B4 (also known as LDH-B),
LDH2-B3A, LDH3-B2A2, LDH4-BA3 and LDH5-A4 (also known
as LDH-A) [12]. Oxamate is an established pyruvate analogue
and competitive inhibitor of LDH-A [13-16]. Oxamate also
inhibits aspartate aminotransferase (AAT), which functions in
tandem with malate dehydrogenase to form the malate-aspar-
tate NADH shuttle. AAT is required to shuttle electrons from
glycolysis-derived cytoplasmic NADH to mitochondrial NADH,
which are then used by the electron transport chain to gener-
ate a proton gradient necessary for oxidative phosphorylation
[17-19]. Importantly, oxamate suppresses the glycolytic flux
and growth of HeLa cervical adenocarcinoma cells [16] and is
selectively toxic to fibroblasts transformed with H-ras [20], an
oncogene that is over-expressed in 50 to 70% of breast ade-
nocarcinomas relative to adjacent normal breast tissues [21-
25]. Given the high activity of LDH in breast tumours and the
potential role of AAT in NADH shuttling into the mitochondria,
we postulated that oxamate, which inhibits both LDH and AAT,
may suppress the growth of human breast adenocarcinomas.
In the current study, we confirm that oxamate has anti-growth
effects on breast cancer cells in vitro and in vivo but find that
the cytostatic effects are secondary to inhibitory effects on
mitochondrial metabolism rather than glycolysis. In particular,
we identify AAT as an essential in situ metabolic target of oxa-
mate and demonstrate that selective inhibition of AAT with
either a carbonyl-trapping agent, amino oxyacetate (AOA) or
AAT-specific siRNA species decreases the proliferation of
breast adenocarcinoma cells. We conclude that AAT may be
essential for the transformation and growth of mammary epi-
thelial cells and may therefore prove to be a valid target for the
development of anti-breast cancer agents.
Materials and methods
Cloning human LDH-A and AAT protein
LDH-A and AAT cDNA were amplified from normal human epi-
thelial cell cDNA using PCR primers designed to flank the
open reading frame. The PCR product was then subcloned
into a pET-30b(+) vector (Novagen, San Diego, CA).
BL21(DE3) Escherichia coli competent cells (Novagen, San
Diego, CA) were transformed with the pET-30b(+)-LDHA and
pET-30b(+)-AAT, C-termHis plasmids. For expression and
purification of protein, 250 mL cultures of BL21-LDHA and
BL21-AAT transformed cells were incubated for 16 hours at
37°C and 250 mL of Luria-Bertani media containing 2 mM iso-
propyl β-D-1-thiogalactopyranoside (final concentration = 1
mM) was added to each culture and shaken for an additional
four hours at 30°C. Bacteria were collected by centrifugation,
and protein purification was performed as described in the
Qiaexpressionist protocol (Qiagen Valencia, CA). Protein con-
centration in elution fractions was quantified using a bicin-
choninic acid protein assay (Pierce Biotechnologies,
Rockford, IL) according to the manufacturer's protocol for
both LDH-A and AAT protein products.
LDH-A assay
The effect of oxamate on LDH-A was measured using purified
human enzyme. In 300 μL of 100 mM sodium phosphate
buffer (pH 7.5), 0.025 to 0.075 units of LDH-A was combined
with reduced β-NADH, 0 to 3 mM sodium pyruvate and
0.033% BSA. Absorbance at 340 nm was measured using a
96-well plate reader to determine the maximum linear change
of absorbance at 340 nm/minute as a measurement of enzyme
activity. LDH activity in the presence of several concentrations
of oxamate was measured and analysed using Sigma Plot
Enzyme Kinetics Module (Systat Software, Richmond, CA).
AAT assay
The effect of oxamate on AAT was measured using purified
human recombinant enzyme. In a 300 μL reaction, 193 mM L-
aspartate, 12 mM α-ketoglutarate, 0.6 units/mL malate dehy-
drogenase, 0.2 mM NAD and 0.03 to 0.06 unit human recom-
binant AAT were combined. Absorbance at 340 nm was
measured using a 96-well plate reader to determine the maxi-
mum linear change of absorbance as a measurement of
enzyme activity. AAT activity, in the presence of several con-
centrations of oxamate was measured to determine in vitro
AAT inhibition. Enzyme activity was analysed using Sigma Plot
Enzyme Kinetics Module (Systat Software, Richmond, CA).
Cell culture
MDA-MB-231 breast adenocarcinoma cells (HTB-26, Ameri-
can Type Culture Collection Manassas, VA) were maintained
in Dulbecco's Modified Eagle's Medium (DMEM) supple-
mented with 10% FCS and gentamicin sulfate (HyClone
Logan, UT). Normal human mammary epithelial cells (HMEC;
Lonza, CC-2551, Walkersville, MD) were maintained in media
formulated with bovine pituitary extract, human epidermalAvailable online http://breast-cancer-research.com/content/10/5/R84
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growth factor, hydrocortisone, GA-1000 and insulin (Lonza,
Walkersville, MD).
In vitro cell proliferation assay
MDA-MB-231 cells and HMEC cells were cultured for 72
hours in identical growth factor-enriched media formulated
with bovine pituitary extract, human epidermal growth factor,
hydrocortisone, GA-1000 and insulin. Several concentrations
of sodium oxamate or AOA (Sigma, St. Louis, MO) were then
added to the media for 48 hours and viable cells were enumer-
ated by light microscopy using trypan blue to exclude dead
cells. The media contained glucose (5 mM) and glutamine (1
mM), and the cells were cultured under 21% oxygen (nor-
moxia) with 5% carbon dioxide at 37°C using a variable car-
bon dioxide tension incubator (Heraeus, Thermo Fisher
Scientific, Asheville, NC). For routine passage, cells were
washed with PBS and trypsinised. Because cultured cells can
undergo mutations, frozen stocks were maintained and active
cultures were restarted from these stocks every 30 days.
Soft agar colony formation assays
MDA-MB-231 cells were plated at a density of 25 × 103 cells
per 60-mm plate with 3 ml bottom agar (0.6%) and 2 ml top
agar (0.3%). HMEC cells served as a negative control,
because they do not grow in soft agar. Cells were fed every
five days by adding a new layer of top agar containing the indi-
cated concentration of oxamate or AOA. After colonies
reached a minimum of 50 μm, they were counted in random 1
cm squared sections of each plate.
MDA-MB-231 xenografts in athymic mice
MDA-MB-231 cells were resuspended in 100 μL PBS and
mixed with 100 μL cold Matrigel basement membrane matrix
(BD Biosciences, Bedford, MA). The resultant mixture (200 μL
containing 10 × 106 cells) was injected subcutaneously into
the flanks of groups of 10 BALB/c nude female mice (average
weight 20 g) per experimental group. When xenografts
reached a mass of 120 mg, a subset of mice received an intra-
peritoneal injection with 15 mg oxamate or 0.2 mg AOA, every
24 hours for 14 days. The mass of the resultant tumours was
determined every 24 hours with vernier calipers according to
the following formula: mass (mg) = [width (mm)]2 × [length
(mm)]/2 [26,27].
These studies followed internationally recognised guidelines
and were approved by the University of Louisville Institutional
Animal Care and Use Committee (IACUC #06007).
Lactate measurements
Lactate concentrations in the media were measured using a
lactate oxidase-based assay read at 540 nm (Trinity, Wicklow,
Ireland). Lactate data were normalised to cell number. Experi-
ments were repeated three times and are expressed as mean
± standard deviation.
Nuclear magnetic resonance
We examined the effect of oxamate or AOA on the flux of glu-
cose carbons into anabolic pathways by capturing 2D nuclear
magnetic resonance (NMR) spectra of MDA-MB-231 cells
treated with oxamate (40 mM) or AOA (100 μM) for 48 hours
in the presence of uniformly labelled 13C-glucose (1 gm/L) (in
glucose-free DMEM, 10% dialysed FCS). For 24 hours, 4 ×
106 MDA-MB-231 cells were plated in T75 cell culture flasks,
then washed with PBS and the media was replaced with
DMEM containing 5 mM [U-13C6]-glucose, 10% dialysed FCS
and gentamicin. Cells were cultured with or without 40 mM
oxamate or 100 μM AOA (5% carbon dioxide, 37°C for 96
hours), trypsinised and cell pellets were washed with PBS.
Cell pellets and supernatants were flash frozen in liquid nitro-
gen, and then ground frozen in liquid nitrogen. The pulverised
samples were lyophilised (5 to 20 mg) and extracted with 20
to 30:1 (v/w) (dried) volumes of 10% (v/v) trichloracetic acid
(TCA), respectively, on ice, before centrifugation. The mixture
was centrifuged (4°C) at 15,000 rpm in an SA-600 rotor (Sor-
vall, DuPont, Wilmington, DE) for 30 minutes, and the super-
natant was removed and saved. The residue was extracted
again, centrifuged and the supernatants were pooled.
Two aliquots (100 to 200 μl each) of the final extract were
lyophilised in 1.5 ml Eppendorf tubes. Dried extract samples
were redissolved in 100% heavy water, centrifuged to remove
particulates and loaded into appropriate NMR tubes. DSS
(2,2-dimethyl-2-silapentane-5-sulfonate sodium) was added
as an internal chemical shift reference and concentration
standard. NMR spectra were recorded at 14.1 T on Varian
Inova NMR spectrometer (Varian, Palo Alto, CA) at 20°C using
a 90° excitation pulse. Total correlation spectroscopy
(TOCSY) experiments used a 6000 Hz spectral width both
dimensions, 0.341 second acquisition time in t2 and 0.05 sec-
ond in t1, a recycle time of 1.84 seconds, a 50 ms mixing time,
and a B1 field strength of 8 kHz generated with MLEV-17.
Metabolites were identified based on their 1H and 13C chem-
ical shifts, and TOCSY connectivity pattern.
Oxygen consumption
MDA-MB-231 cells were grown in oxamate (40 mM) or AOA
(100 μM) for 24 hours. Subsequently, cells were detached
with trypsin-ethylenediaminetetraacetic acid (EDTA), and cen-
trifuged at 1000 rpm for five minutes in complete culture
medium. Oxygen consumption was measured using a
Strathkelvin 782 Oxygen Meter (Strathkelvin Instruments Ltd.
Glasgow Scotland, UK). Respiration rates were measured
using 5 × 106 cells suspended in a total volume of 525 μL
DMEM containing 10% FBS at 37°C for 10 minutes.
Cellular ATP determination
Cellular ATP was measured using a bioluminescence assay
determination kit (Molecular Probes, Invitrogen, Carlsbad,
CA.) The assay relies on the requirement of ATP by luciferaseBreast Cancer Research    Vol 10 No 5    Thornburg et al.
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to produce light (emission maximum about 560 nm at pH 7.8).
Briefly, after 24 hours of growth in oxamate (40 mM) or AOA
(100 μM), 1 × 106 cells were resuspended in reaction buffer
containing 1 mM dithiothreitol (DTT), 0.5 mM luciferin and
12.5 μg/ml luciferase, gently mixed, and measurements were
obtained in a luminometer (TD-20/20, Turner Designs, Sunny-
vale, CA). ATP standard curves were run concurrently with
each experiment to produce a standard curve, and calcula-
tions were made against the curve to determine cellular ATP
levels (expressed as mol/106 cells).
NAD+/NADH ratio assay
MDA-MB-231 cells were grown to 70% confluency in a 10
cm2 tissue culture plate in appropriate media (as described
above). Cells were subsequently treated with media contain-
ing oxamate (40 mM) or AOA (100 μM). After 24 hours of
treatment, cells were lifted with trypsin, washed twice with
PBS and 1 × 106 cells were pelleted through centrifugation.
NADH and NAD+ were determined according to manufac-
turer's protocol (#ECND-100, Bioassay Systems, Hayward,
CA). Briefly, cell pellets were resuspended in 1.5 mL Eppen-
dorf tubes with either 100 μl NAD+ extraction buffer (contain-
ing 0.40% hydrochloric acid) for NAD determination or 100 μl
NADH extraction buffer (containing 0.40% sodium hydroxide)
for NADH determination. Extracts were heated for five minutes
at 60°C and 20 μl of assay buffer (containing Tris (hydroxyme-
thyl) aminomethane 3.0% and BSA 0.10%) was added fol-
lowed by the extraction buffer (to neutralise the extracts).
Mixtures were vortexed and centrifuged at 13,000 rpm for five
minutes. Supernatants were added to working reagent con-
taining assay buffer, alcohol dehydrogenase, ethanol, phena-
zine methosulfate (PMS) and tetrazolium dye (MTT). Optical
density at 565 nm was recorded at time zero and at 15 min-
utes using a 96-well plate reader spectrophotometer. Differ-
ence in absorbance was compared with standard solutions
and used to calculate NADH and NAD+ concentrations.
Ectopic expression of AAT
MDA-MB-231 cells were transfected with the open reading
frame of the human cytoplasmic AAT using the pIRESneo3
vector (Clontech, Mountain View, CA), to create MDA-MB-
231/AAT+ cells. MDA-MB-231 cells were also transfected
with the empty pIRES/neo3 vector alone to create MDA-MB-
231/vect cells as a negative control. This vector contains an
internal ribosome entry site (IRES), thus permitting the transla-
tion of two open reading frames from one mRNA. After selec-
tion with 500 μg/ml neomycin, surviving cells stably expressed
AAT (as confirmed with Western blot). All transfections were
carried out using Lipofectamine (Invitrogen, Carlsbad, CA) as
a transfection reagent. MDA-MB-231/AAT+ cells were culti-
vated in DMEM supplemented with 10% FCS and gentamycin
sulfate (HyClone) containing 250 μg/ml neomycin.
siRNA transfection
Cells were plated at a concentration of 65 × 103 cells per well
in six-well tissue culture plates (or 1 × 106 cells/T150 flasks)
and incubated in 5% carbon dioxide and 37°C in DMEM as
described above for 24 hours. Cells were then transfected
with siRNA for a final concentration of 100 nM using Oligo-
fectamine (Invitrogen, Carlsbad, CA) as a transfection reagent
according to the manufacturer's protocol. Three siRNA con-
structs were obtained from a predesigned siRNA library
(Ambion, Applied Biosystems, Austin, TX), one targeting exon
#4 of the GOT1 mRNA product (AAT1), one targeting exon
#3 of the GOT1 mRNA product (AAT2) and one crossing
exons #1 and 2 of the GOT1 mRNA product (AAT3). A non-
specific siRNA and Oligofectamine alone were included as
negative controls. After transfection, cells were incubated for
48 hours where cells were counted and protein levels were
quantified using Western blot analysis.
Results
Oxamate inhibits human recombinant LDH-A and AAT
The enzyme kinetics of LDH and the inhibitory effects of oxam-
ate on LDH using enzyme purified from rabbit muscle (LDH-A)
or porcine heart (LDH-B) have been previously examined
[19,27,28]. However, no studies have examined the effects of
oxamate on purified human LDH-A and differences between
the rabbit and human LDH-A amino acid sequences (77%
homology) may result in differences in the affinity of oxamate.
We produced recombinant human LDH-A and conducted ini-
tial kinetic studies that indicated that the Vmax of human LDH-
A is 117 μmol/minute/mg protein and the Km for pyruvate is
111.8 μM (Figures 1a and 1b). We confirmed that oxamate
competitively inhibits the activity of human LDH-A in vitro, with
a Ki of 136.3 μM (using pyruvate as substrate). These data
indicate that oxamate is a competitive inhibitor of human LDH-
A and thus may prove useful for an examination of the effects
of LDH-A inhibition on human breast adenocarcinoma cell
proliferation.
Oxamate also has previously been found to inhibit purified
AAT, an enzyme involved in mitochondrial metabolism via the
tricarboxylic acid cycle and the malate-aspartate shuttle
[17,28]. Specifically, oxamate can competitively inhibit AAT
with respect to 2-oxoglutarate (α-ketoglutarate), having a Ki of
28  μM. We confirmed that oxamate inhibits the activity of
recombinant human recombinant AAT in vitro (Vmax = 5.2
μmol/minute/mg protein, Km = 379.1 μM, Ki = 30.3 μM; Fig-
ure 1c). Lineweaver-Burk analyses indicated that the inhibitory
effects were almost completely competitive with α-ketoglutar-
ate (Figure 1d).
Oxamate decreases the channeling of glucose-derived 
carbons into products of the tricarboxylic acid cycle
Given the sensitivity of human LDH-A to oxamate, we assumed
that oxamate would reduce the cellular production of lactate.
We examined the effect of oxamate on lactate secretion byAvailable online http://breast-cancer-research.com/content/10/5/R84
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MDA-MB-231 cells and, surprisingly, observed no difference
in the lactate secreted per cell (control, 89 ± 11 mg/dL per
106 cells; +40 mM oxamate, 88 ± 14 mg/dL per 106 cells). In
order to better clarify the metabolic consequences of oxamate
on glycolytic flux, we pulsed MDA-MB-231 cells with uni-
formly-labelled [U-13C6]-glucose and examined the fate of the
13C using 2D-NMR-TOCSY analyses. Figures 2a and 2b
show the regions of the TOCSY spectra of untreated and oxa-
mate-treated MDA-MB-231 cells that contain several metabo-
lites of interest, including glutamate/glutathione, lactate and
alanine. Specifically, the cross peaks at 1.40/4.38 ppm repre-
sent 12C-lactate, while the satellite peaks (at the corners of the
identifying squares) represent 13C-labelled lactate. We con-
firmed equal 13C-enrichment of intracellular lactate from the
[U-13C6]-glucose in the untreated and oxamate-treated cells
(compare Figures 2a and 2b). These data demonstrate that
oxamate exposure to MDA-MB-231 cells is not causing signif-
icant inhibition of LDH-A activity in situ.
In Figures 2a and 2b, the peaks at 2.60/4.05 ppm and 2.20/
4.05 ppm represent the glutamate/glutathione moieties with
satellite peaks (again at the corners of the identifying squares)
representing  13C-labelled glutamate/glutathione. We
observed less 13C-labelled glutamate/glutathione in the oxam-
ate-treated group (Figure 2b), which suggests that oxamate
may decrease the conversion of glucose-derived 13C into
glutamate. Glucose is converted to pyruvate via the glycolytic
pathway, which is then either converted to lactate via LDH-A
or funneled into the tricarboxylic acid cycle in the mitochon-
dria. Through the tricarboxylic acid cycle, carbons deriving
from pyruvate can be incorporated into several metabolites
associated with the tricarboxylic acid cycle including gluta-
mate. Based on the observations that there is less 13C-enrich-
ment of glutamate in the oxamate-treated cells and that there
is no difference in 13C incorporation into lactate, we surmise
that oxamate may be suppressing the tricarboxylic acid cycle.
Figures 2c and 2d show the cross peak pattern centered at
8.00/5.95 ppm corresponding to the H6, H5 ring protons of
uridine (UTP and UDP). The carbons of uridine are derived
from aspartate, which is produced by the transamination of
oxaloacetate from the tricarboxylic acid cycle. The satellite
peaks in the untreated MDA-MB-231 cells (Figure 2c) indicate
that the uridine base (UXP) incorporates carbons from normal
tricarboxylic acid cycling in which the 13C-label enters as
acetyl coenzyme A (via pyruvate dehydrogenase) and from
anapleurotic reactions in which adjacent carbons from pyru-
vate are converted into oxaloacetate via pyruvate carboxylase.
However, these satellite peaks are completely absent after
oxamate treatment suggesting that the 13carbons are not
being incorporated into uridine, and that normal tricarboxylic
Figure 1
Oxamate inhibits human recombinant lactate dehydrogenase A (LDH-A) and aspartate aminotransferase (AAT) activity in vitro Oxamate inhibits human recombinant lactate dehydrogenase A (LDH-A) and aspartate aminotransferase (AAT) activity in vitro. (a) Recom-
binant enzyme assays using purified human LDH-A were performed as described. (b) Lineweaver-Burk double reciprocal plots examining LDH-A 
enzyme activity as a function of pyruvate concentration. Kinase assays were performed in the presence or absence of 80, 240 or 800 μM oxamate. 
(c) In vitro recombinant enzyme assays using purified human AAT were performed as described. (d) Lineweaver-Burk double reciprocal plots exam-
ining AAT enzyme activity as a function of α-ketoglutarate (KG) concentration. Kinase assays were performed in the presence or absence of 15, 30 
or 40 mM oxamate. Data are plotted as the mean ± standard deviation.Breast Cancer Research    Vol 10 No 5    Thornburg et al.
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acid cycling in MDA-MB-231 cells is inhibited by oxamate
treatment (Figure 2d).
We examined oxygen consumption, a direct measure of elec-
tron transport chain activity, by MDA-MB-231 cells with and
without exposure to 40 mM oxamate for 24 hours (a period
that precedes any cytostatic effects) and observed a 61%
decrease in the rate of oxygen consumption (5 × 106 cells per
group; Figure 2e). We also found that oxamate reduced the
steady-state concentration of ATP after 24 hours (33 ± 3%
reduction in ATP per cell; Figure 2f) and observed a small but
statistically significant decrease in the NAD+/NADH ratio of
MDA-MB-231 cells treated with 40 mM oxamate (untreated,
NAD+ = 9.41 ± 0.63 μM, NADH = 7.02 ± 0.33 μM, NAD+/
NADH = 1.34; + 40 mM oxamate, NAD+ = 9.68 ± 0.54 μM,
NADH = 8.11 ± 0.33 μM, NAD+/NADH = 1.19). We suspect
that this only limited decrease in the NAD+/NADH ratio may
reflect compensation by the multitude of other enzymes that
use NAD+/NADH as cofactors.
AOA decreases the channeling of glucose-derived 
carbons into products of the tricarboxylic acid cycle
AAT is a pyridoxal phosphate-dependent enzyme that plays a
major role in amino acid metabolism and the tricarboxylic acid
cycle. When coupled to the malate dehydrogenase enzymes,
AAT catalyses the activity of the malate-aspartate NADH shut-
tle, which faciliates the net transfer of reducing equivalents
across the mitochondrial membrane [29]. Specifically, AAT is
responsible for the interconversion of aspartate and glutamate
with the co-conversion of α-ketoglutarate and oxaloacetate.
Inhibition of AAT rather than LDH-A would be expected to
reduce the conversion of glucose-derived carbons into gluta-
mate and uridine, and to decrease oxygen consumption.
Amino oxyacetate is a carbonyl-trapping agent that inhibits
AAT because of its dependence on pyridoxal phosphate as a
Figure 2
Oxamate inhibits the conversion of glucose into several products of the tricarboxylic acid cycle, oxygen consumption and intracellular ATP Oxamate inhibits the conversion of glucose into several products of the tricarboxylic acid cycle, oxygen consumption and intracellular ATP. 
MDA-MB-231 cells were grown in medium containing 1 g/L [U-13C6]-glucose and exposed to either (a, c) PBS or (b, d) 40 mM oxamate. After 48 
hours, live cells were washed, extracted with 10% trichloracetic acid (TCA), lyophilised and dissolved in 100% heavy water. The spectrum was 
recorded at 14.1 T with a recycle time of five seconds under standardised conditions of acquisition. 13C-isotopomers were quantified by indirect 
detection of protons in the 2D-NMR total correlation spectroscopy (TOCSY) spectrum. The four peaks representing the 13C-labelled glutamate/glu-
tathione (Glu/GSH), alanine (Ala) and (a, b) lactate and (c, d) uridine bases are highlighted with red squares. Cells were cultured in the presence or 
absence of 40 mM oxamate for 24 hours and then (e) oxygen consumption was measured using an oxygen meter and (f) ATP concentration was 
determined with a luminometer as detailed. ATP standard curves were run concurrently. Data are plotted as the mean ± standard deviation.Available online http://breast-cancer-research.com/content/10/5/R84
Page 7 of 12
(page number not for citation purposes)
co-enzyme [30]. This inhibition is directly related to the con-
centration of AOA used [31]. Although the Ki value for AOA is
not published, it has been previously identified as only a mod-
erately potent inhibitor of AAT in vivo, requiring 1.0 mM to
achieve sufficient inhibition [32]. However, more recent
research indicates that AOA is more efficacious in inhibiting
the M-A shuttle, requiring only 0.1 mM for AAT inhibition in
vivo [30].
We confirmed that AOA inhibited recombinant human cyto-
plasmic AAT (IC50 = 515 ± 35 μM) and then examined the
effect of 100 μM AOA on the fate of uniformly labelled [U-
13C6]-glucose using 2D-NMR-TOCSY analyses. Figures 3a
and 3b demonstrate the regions of the TOCSY spectra of
untreated and AOA-treated MDA-MB-231 cells that contain
the glutamate/glutathione, lactate and alanine peaks. The
effects of AOA on glucose metabolism mirrored those
observed after oxamate exposure. We observed a reduction in
the 13C-labelled glutamate/glutathione satellite peaks and no
decrease in 13C incorporation into lactate after exposure to
AOA (Figure 3b). We also found that the uridine satellite
peaks were completely abrogated by AOA treatment
suggesting that the 13carbons are not being incorporated into
uridine (Figure 3d).
Taken together, these data indicate that exposure of MDA-
MB-231 cells to AOA, like oxamate, inhibits tricarboxylic acid
cycling. We were surprised by the observed reduction in
alanine by AOA (Figure 3b) and can only speculate that
increased cytoplasmic NADH may promote conversion of
pyruvate to lactate by LDH and thus reduce available substrate
for alanine (i.e. pyruvate). Similar to oxamate exposure, AOA
Figure 3
Amino oxyacetate (AOA) inhibits the conversion of glucose into several products of the tricarboxylic acid cycle, oxygen consumption and intracellular  ATP Amino oxyacetate (AOA) inhibits the conversion of glucose into several products of the tricarboxylic acid cycle, oxygen consumption and 
intracellular ATP. MDA-MB-231 cells were grown in medium containing 1 g/L [U-13C6]-glucose and exposed to either (a, c) PBS or (b, d)100 μM 
AOA. After 48 hours, live cells were washed, extracted with 10% trichloracetic acid (TCA), lyophilised and dissolved in 100% heavy water. The 
spectrum was recorded at 14.1 T with a recycle time of five seconds under standardised conditions of acquisition. 13C-isotopomers were quantified 
by indirect detection of protons in the 2D-NMR total correlation spectroscopy (TOCSY) spectrum. The four peaks representing the 13C-labelled 
glutamate/glutathione (Glu/GSH), alanine (Ala) and (a, b) lactate and (c, d) uridine bases are highlighted with red squares. Cells were cultured in the 
presence or absence of 100 μM AOA for 24 hours and then (e) oxygen consumption was measured using an oxygen meter and (f) ATP concentra-
tion was determined with a luminometer as detailed. ATP standard curves were run concurrently. Data are plotted as the mean ± standard deviation.Breast Cancer Research    Vol 10 No 5    Thornburg et al.
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inhibited oxygen consumption, reduced the steady-state con-
centration of ATP after 24 hours (Figures 3e and 3f) and
decreased the NAD+/NADH ratio of MDA-MB-231
(untreated, NAD+/NADH = 1.29; + 100 μM AOA, NAD+/
NADH = 1.01).
Oxamate and AOA suppress MDA-MB-231 breast 
adenocarcinoma growth
We examined the effects of several concentrations of oxamate
or AOA on the proliferation of MDA-MB-231 human breast
adenocarcinoma cells relative to normal HMECs. Figures 4a
and 4b demonstrate that exposure to either oxamate or AOA
causes a selective inhibition of growth of MDA-MB-231 trans-
formed mammary epithelial cells when compared with
HMECs. Neoplastic transformation of mammary epithelial cells
confers the ability for anchorage-independent growth. We cul-
tivated colonies of MDA-MB-231 cells in soft agar in the pres-
ence of several concentrations of oxamate or AOA. We found
that exposure to oxamate or AOA inhibits soft agar colony for-
mation at concentrations that closely mirror the inhibition of
anchorage-dependent proliferation (Figures 4c and 4d). We
next examined the effect of intraperitoneal administration of
oxamate or AOA on the growth of established MDA-MB-231
breast tumours in athymic mice. MDA-MB-231 cells were
injected subcutaneously into the flanks of groups of BALB/c
athymic female mice and, after the tumours had grown to
about 120 mg, the mice were randomised to receive a control
injection of PBS, 15 mg oxamate or 0.2 mg AOA in PBS daily
for 14 days. We found that both oxamate and AOA sup-
pressed the growth of MDA-MB-231 tumours within 48 hours
of treatment initiation (Figures 4e and 4f). Taken together,
these data indicate that transformed mammary epithelial cells
may be selectively sensitive to AAT inhibition.
AAT is required for breast cancer cell proliferation
In order to directly address the hypothesis that AAT inhibition
is required for the cytostatic effects of oxamate, we stably
expressed AAT in MDA-MB-231 cells and examined these
cells for cytostatic sensitivity to oxamate. We confirmed
increased AAT expression by Western blot analysis (Figures
5a and 5b) and found that the over-expression of AAT con-
ferred resistance to the cytostatic effects of oxamate (Figure
5c; IC50 values = MDA-MB-231 cells, 39 ± 6.0 mM; MDA-MB-
231/+AAT cells, 68 ± 5.6 mM; MDA-MB-231/vector control,
41 ± 6.2 mM). In order to directly examine the requirement of
AAT for MDA-MB-231 cell proliferation, we transfected the
cells with three separate AAT-specific siRNA species (AAT1-
3) and confirmed that AAT1 and AAT3 selectively inhibit AAT
protein expression relative to β-Actin (Figures 5d and 5e).
Selective AAT inhibition caused a marked reduction in cell pro-
liferation as determined after 48 hours of transfection (Figure
5f). Collectively, these data provide support for the role of AAT
as an essential metabolic target of oxamate and as a potential
target for the development of anti-neoplastic agents.
Discussion
We have demonstrated that oxamate and AOA selectively
inhibit the proliferation of transformed breast adenocarcinoma
cells in vitro and suppress the growth of established breast
adenocarcinoma xenografts in athymic mice. Although we
confirmed that oxamate inhibited recombinant LDH-A, we also
found that oxamate decreased the activity of AAT, a key
enzyme required for the malate-aspartate NADH shuttle and
an enzymatic target of AOA. We found that oxamate reduced
the flux of glucose-derived carbons into several mitochondrial
tricarboxylic acid cycle products and reduced oxygen con-
sumption but had little effect on the glycolytic flux into lactate.
Importantly, we established the requirement of AAT for breast
adenocarcinoma cell proliferation by finding that ectopic
expression of AAT in MDA-MB-231 cells confers resistance to
the anti-proliferative effects of oxamate, and that AAT-specific
siRNA molecules decrease MDA-MB-231 growth in vitro.
Taken together, these data indicate that AAT may be a novel
target for the development of anti-breast cancer agents.
In order to enable untethered flux at multiple energetic and
anabolic enzymes, NADH production must be balanced with
NADH oxidation to NAD+. Although mitochondrial NADH can
be directly oxidised in the electron transport chain, cytoplas-
mic NADH cannot directly traverse the mitochondrial mem-
brane. Three NADH shuttle systems operate to transfer
electrons from cytoplasmic NADH to mitochondrial NAD+: the
α-glycerophosphate shuttle, fatty acid shuttle and the malate-
aspartate shuttle [17-19,33,34]. Cytoplasmic AAT and mito-
chondrial AAT function in tandem with malate dehydrogenase
to cycle the malate-aspartate shuttle. Specifically, cytoplasmic
malate can enter the mitochondria via a malate-α-ketoglutarate
antiporter and be converted to oxaloacetate by malate dehy-
drogenase, resulting in the reduction of mitochondrial NAD+
to NADH. Oxaloacetate cannot traverse the mitochondrial
membrane but is converted by mitochondrial AAT into aspar-
tate, which then enters the cytoplasm via the glutamate-aspar-
tate antiporter and is converted by cytoplasmic AAT to
oxaloacetate. This newly generated cytoplasmic oxaloacetate
is then converted to malate by malate dehydrogenase, which
results in the oxidation of cytoplasmic NADH and completes
the shuttle cycle.
The malate-aspartate shuttle is active in the neoplastic cells of
several types of tumours and is believed to account for about
20% of the total respiratory rate and to allow mitochondrial oxi-
dation of the significant fraction of glycolytic NADH that is not
oxidised by LDH-A (13 to 80% depending on the cell type [17-
19,33,34]). The activities of the two essential enzymes of the
malate-aspartate shuttle, AAT and glutamate dehydrogenase,
are increased as a result of a combination of H-ras and carcin-
ogen (diethylnitrosamine) induced transformation in vivo [33].
We speculate that the observed reduction in mitochondrial
metabolism by oxamate and the reliance of the cytostatic
effects of oxamate on AAT expression may be related to anAvailable online http://breast-cancer-research.com/content/10/5/R84
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essential requirement for this shuttle to be at least minimally
active in rapidly dividing breast cancer cells. LDH activity has
previously been found to account for the majority of the
NADH-oxidising activity when compared with the malate-
aspartate shuttle in transformed cells [34]. Although we found
that oxamate inhibits both recombinant LDH-A and AAT, the
NMR-TOCSY spectra presented herein suggest that flux
through AAT may be markedly more sensitive to pharmacolog-
ical inhibition by oxamate in situ. These data are surprising
since oxamate was found to be a far more potent inhibitor of
LDH-A than AAT (Figure 1). We can only speculate that the
intracellular compartmentalisation of oxamate relative to its
enzyme targets, LDH-A and AAT, or the intracellular equilib-
rium between the substrates and products of these two
enzymes favours the in situ inhibition of AAT rather than LDH-
A.
In human tissues, both cytoplasmic AAT and mitochondrial
AAT proteins consist of a compartment-specific homodimer
that are encoded by separate genes, GOT1 and GOT2,
respectively. Although the crystal structures of the human
cytoplasmic AAT and the mitochondrial AAT isoforms have not
been solved, the structures of AAT from several other species
have been determined, including E. coli [35-38], the cytosolic
Figure 4
Oxamate and amino oxyacetate (AOA) are selectively toxic to MDA-MB-231 transformed human mammary epithelial cells (HMEC) and suppress the  growth of established breast tumour xenografts in vivo Oxamate and amino oxyacetate (AOA) are selectively toxic to MDA-MB-231 transformed human mammary epithelial cells (HMEC) and 
suppress the growth of established breast tumour xenografts in vivo. Growth inhibition studies were performed as described. MDA-MB-231 
cells or HMEC were cultured in identical media for 48 hours in the absence or presence of the indicated concentrations of (a) oxamate or (b) AOA. 
Cells were exposed to trypan blue and enumerated using light microscopy (dashed line indicates percentage control at time of plating). MDA-MB-
231 cells at a concentration of 2.5 × 104 were plated on 6 cm dishes containing Dulbecco's Modified Eagle's Medium (DMEM) with 0.6% agar in 
the absence or presence of the indicated concentrations of (c) oxamate or (d) AOA. Cells were fed with 0.2% agar in media containing oxamate 
every three to five days. After 28 days, soft agar colonies were enumerated and expressed as a percentage of control. MDA-MB-231 xenografts 
were initiated as described. Tumours were measured daily using blunt end Vernier calipers, and mice with established tumours (130 to 190 mg) 
were blindly randomised into either PBS control ( ● ) or treatment ( ○ ) groups. Experimental mice were weighed, and given daily intraperitoneal 
injections of either PBS or (e) 15 mg oxamate or (f) 0.2 mg AOA. Data are plotted as the mean ± standard deviation.Breast Cancer Research    Vol 10 No 5    Thornburg et al.
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and mitochondrial isoforms from chickens [35-42] and the
cytosolic form from pigs [43]. Analysis of these crystal struc-
tures using a least-squares minimum overlay found that the
proteins, regardless of origin, have an identical peptide fold
and active site residues [44]. Given the high residue sequence
homology between human and pig cytoplasmic AAT, the terti-
ary structure of human AAT should be easily deducible via
computational modelling. Based on this homology model,
small molecule inhibitors of AAT then can be identified through
the use of virtual screening, a computational technique that
can prescreen vast databases of small molecule structures
against a three-dimensional structure to see which of these
dock into a chosen substrate-binding site. Accordingly, we
predict that AAT may be a 'druggable' metabolic target for the
development of anti-breast cancer agents.
Conclusions
Taken together, these observations support an examination of
the role of AAT in the neoplastic metabolism, transformation
and growth of mammary epithelial cells. Future studies will be
directed at generating a cre-lox heterozygous knockout of AAT
as well as examining the relative effects of lentivirus-driven
small hairpin RNA silencing of AAT on normal and transformed
mammary epithelial cells. Importantly, heterozygous genomic
deletions of several metabolic enzymes that are essential for
neoplastic transformation have been found not to result in
developmental or growth abnormalities [45-48], and we pos-
tulate that certain metabolic enzymes such as AAT may prove
to be the Achilles' heel of breast cancer cells.
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